highly correlated (r 2 >0.9) SNPs. All statistical analyses were conducted using R version 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria), and the R package MendelianRandomization. No Institutional Review Board approval was required because the data are publicly available.
Genetically instrumented CT-pro-ET-1 was positively associated with IHD using IVW (odds ratio [ (Table) . After excluding rs2545801 for IHD and MI because of its associations with potentially IHDrelated attributes identified using PhenoScanner, such as activated partial thromboplastin time and Factor XII antigen, the IVW estimates were similar (Table) .
In this first MR study of the effects of a biomarker of ET-1 on IHD, we found higher CT-pro-ET-1 might cause IHD, but was not related to diabetes mellitus or lipids. We took advantage of very large genetic studies, nevertheless, limitations exist. We used only 3 SNPs for CTpro-ET-1, but they explained a substantial proportion of the variance. Confounding by population stratification is possible, but the genetic associations are from separate studies in ancestrally similar populations 2 with genomic control as appropriate. The genetic predictors of CT-pro-ET-1 might affect IHD other than via CT-pro-ET-1, but we obtained similar results after excluding rs2545801 (Table) . Whether the metabolites found by PhenoScanner associated with rs2545801 (phenylalanine and alanine to phenylalanine ratio) and rs4253237 (alanine to histidine ratio, histidine, histidine to valine ratio, phenylalanine to valine ratio, B-type natriuretic peptide, and bradykinin) affect IHD other than via CT-pro-ET-1 is unknown, but these metabolites are not clearly known to affect IHD. Adrenomedullin is highly correlated with and stimulated by ET-1. 2, 3 The role of adrenomedullin in IHD is uncertain, replicated SNPs predicting adrenomedullin are too limited to determine an effect on IHD or MI using MR.
2,3 MR-Egger did not give any statistical indications of pleiotropy, but with only 3 SNPs power to detect pleiotropy may be low. We rely on the validity of the conduct and presentation of the underlying studies. 2 We could not assess whether associations with IHD varied by age, sex, ethnicity, or baseline levels of CT-pro-ET-1. However, causal factors should act consistently, but might not be relevant in all settings.
Our findings have some consistency with the recently discovered effects of ET-1 expression on IHD, 1 and with ET-1 promoting atherosclerosis in mice. 4 Notably, ET-1 is also regulated by several potential targets of intervention, including dietary, environmental, and endocrine factors, 5 as well as existing therapeutics. Our study provides further evidence that factors regulating ET-1 might be targets of intervention to combat IHD. 
ACKNOWLEDGMENTS

